ViiV Healthcare
Clinical trials sponsored by ViiV Healthcare, explained in plain language.
A global specialist HIV company, majority-owned by GSK.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New HIV antibody VH4527079 enters early human safety testing Results expected Sep 2026 (estimated)
- New HIV prevention shot could last 4 months Results expected Sep 2026 (estimated)
- Can a new drug combo flush out hidden HIV? Results expected Jan 2027 (estimated)
- New HIV pill VH4770359 enters first human safety tests Results expected May 2027 (estimated)
- New HIV prevention shot gets a boost: enzyme may make injections last longer Results expected Jun 2027 (estimated)
-
Can two shots replace daily HIV pills? trial tests new injectable combo
Disease control Not yet recruitingResearchers are testing whether a two-drug injectable regimen can control HIV in adults who have not yet started treatment. The trial pairs an experimental drug called VH4011499 with cabotegravir, an existing injectable HIV medicine, and compares different dose combinations again…
Phase 2 • Sponsor: ViiV Healthcare • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New injectable HIV prevention drug tested in healthy volunteers
Prevention Not yet recruitingResearchers are testing a new injectable drug called VH5356136 to see if it is safe and how the body processes it. The trial enrolls about 160 healthy adults without HIV, ages 18 to 55. Participants receive a single dose of the drug or a placebo, and researchers monitor side effe…
Phase 1 • Sponsor: ViiV Healthcare • Aim: Prevention
Last updated Sep 18, 2026 00:00 UTC
-
New injectable HIV prevention candidate tested for safety
Prevention Not yet recruitingResearchers are testing an experimental injectable drug called VH4367310 in healthy adults aged 18 to 55. The drug is a long-acting form of cabotegravir, a medicine already used to prevent HIV. This phase 1 trial gives a single increasing dose to measure how the body processes th…
Phase 1 • Sponsor: ViiV Healthcare • Aim: Prevention
Last updated Sep 16, 2026 00:00 UTC